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Abstract
Purpose—To report dosimetry and early toxicity data in breast cancer patients treated with
postoperative proton radiation therapy.
Methods and Materials—From March 2013 to April 2014, 30 patients with nonmetastatic
breast cancer and no history of prior radiation were treated with proton therapy at a single proton
center. Patient characteristics and dosimetry were obtained through chart review. Patients were
seen weekly while on treatment, at 1 month after radiation therapy completion, and at 3- to 6month intervals thereafter. Toxicity was scored using Common Terminology Criteria for Adverse
Events version 4.0. Frequencies of toxicities were tabulated.
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Results—Median dose delivered was 50.4 Gy (relative biological equivalent [RBE]) in 5 weeks.
Target volumes included the breast/chest wall and regional lymph nodes including the internal
mammary lymph nodes (in 93%). No patients required a treatment break. Among patients with >3
months of follow-up (n = 28), grade 2 dermatitis occurred in 20 patients (71.4%), with 8 (28.6%)
experiencing moist desquamation. Grade 2 esophagitis occurred in 8 patients (28.6%). Grade 3
reconstructive complications occurred in 1 patient. The median planning target volume V95 was
96.43% (range, 79.39%-99.60%). The median mean heart dose was 0.88 Gy (RBE) [range, 0.01–
3.20 Gy (RBE)] for all patients, and 1.00 Gy (RBE) among patients with left-sided tumors. The
median V20 of the ipsilateral lung was 16.50% (range, 6.1%–30.3%). The median contralateral
lung V5 was 0.34% (range, 0%–5.30%). The median maximal point dose to the esophagus was
45.65 Gy (RBE) [range, 0–65.4 Gy (RBE)]. The median contralateral breast mean dose was 0.29
Gy (RBE) [range, 0.03–3.50 Gy (RBE)].
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Conclusions—Postoperative proton therapy is well tolerated, with acceptable rates of skin
toxicity. Proton therapy favorably spares normal tissue without compromising target coverage.
Further follow-up is necessary to assess for clinical outcomes and cardiopulmonary toxicities.

Reprint requests to: Oren Cahlon, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065. Tel: (212)
639-5219; cahlono@mskcc.org.
Conflict of interest: B.C., H.T., and O.C. have minority investment in ProCure Proton Therapy Center, Somerset, NJ.
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Introduction
Adjuvant radiation therapy for breast cancer has been shown to improve overall survival
after mastectomy (1–3) and contribute to longer breast cancer–specific survival after breastconservation surgery (4). For patients with a high risk of nodal failure after surgery,
comprehensive coverage of the axillary and supraclavicular lymph nodes within the
radiation target is indicated. Recent data also suggest that inclusion of the internal mammary
lymph nodes (IMNs) increases survival among select patients (5, 6).
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Treatment to these areas with traditional irradiation techniques can encompass a significant
amount of normal tissue, including the heart, lungs, and contralateral breast. Patients
receiving radiation for breast cancer are subsequently at risk for cardiopulmonary toxicity
(7–12) and secondary cancers (13, 14). Much effort has been directed at avoiding normal
structures while still managing to target areas at risk for recurrence.
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With traditional photon therapy techniques, target coverage can be compromised in efforts to
minimize dose to the critical structures (15). Highly conformal techniques, such as intensity
modulated radiation therapy (IMRT) and volumetric modulated arc therapy, can improve
coverage but lead to higher levels of low and intermediate doses to surrounding organs.
Proton therapy has the unique ability to achieve full coverage of the target tissue and
simultaneous optimal organ sparing. This sparing is made possible by the rapid fall-off of
dose distal to the target. Despite the potential benefits, clinical use of proton therapy for
breast cancer is limited. Although several groups have reported outcomes for partial breast
irradiation in early-stage breast cancer (16–18), the literature surrounding the use of proton
therapy for locally advanced breast cancer consists of a single publication from the
Massachusetts General Hospital on early outcomes for 12 patients treated on an institutional
protocol (19). Furthermore, there are no published clinical data to date for the use of proton
therapy in the treatment of the whole breast and regional lymph nodes. We report the early
experience at a single proton center in treating breast cancer patients with adjuvant proton
therapy, in both the postmastectomy and postlumpectomy setting for breast cancer.

Methods and Materials
Patient population
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In 2013 a breast cancer treatment program was initiated at Procure Proton Therapy Center
(Somerset, NJ). From March 2013 to April 2014, 30 consecutive patients with nonmetastatic
breast cancer and no history of prior chest wall radiation therapy were treated with
postoperative proton radiation therapy. These patients were not part of a clinical trial.
Patients were generally referred because of unfavorable cardiopulmonary anatomy.
Postlumpectomy patients were not offered treatment if large breast size (defined as having
breast anatomy that was prone to significant interfraction mobility) would preclude accurate
setup. Patient and treatment characteristics were extracted from a prospective database and
are summarized in Table 1.
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Patients were simulated with a CT scan in the supine position using a custom mold for
immobilization. Xio treatment planning software (Elekta, Stockholm, Sweden) was used for
treatment planning. Artifacts seen on the planning CT scan were addressed on a per-patient
basis with manual electron density override. Clinical target volumes (CTVs) and normal
structures were contoured according to Radiation Therapy Oncology Group (RTOG)
guidelines (20), with the exception of the supraclavicular fossa and exclusion of the ribs and
intercostals. For the supraclavicular lymph node group, the volume was modified in the
majority of cases to encompass the portion of the fossa that is deep and posterior to the
sternocleidomastoid (analogous to level V of the neck). This area is a known site of nodal
metastases and failure (21) and is usually covered with photons, because an anterior oblique
field deposits a gradient of dose throughout the entire width of the patient. When using
proton therapy to treat this area, it is important to extend the range of the en face beam to
include the posterior supraclavicular fossa. We therefore routinely include this area in the
treatment volume for patients undergoing postoperative proton therapy. This volume
modification is illustrated in Figure 1. For planning target volume (PTV) expansion, the
CTV was expanded by 7 mm laterally. In the distal/posterior direction, the plan was
generated to cover the CTV, and the plan was evaluated for range uncertainty of ±(2.5% + 2
mm). A smear radius of 7 mm, equal to the lateral setup uncertainty, was also used. The
PTV also flashed the skin anteriorly by 5 mm.
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In the initial experience the CTV was drawn medially to the edge of the esophagus. An
additional margin was added medially for PTV, which subsequently overlapped with the
esophagus. Because of detection of mild esophagitis in 3 of the first 5 patients treated, the
contouring technique was later modified so that no PTV margin was added around the
esophagus, and PTV overlap was eliminated. This modification is illustrated in Figure 2.
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Proton therapy was delivered with uniform scanning beams. The beam arrangement included
an anteriorly oriented field encompassing the chest wall and regional lymph nodes, which
was matched to an anteriorly directed supraclavicular fossa field. To feather the match, a set
of beams with the same orientation and targets but with a match line that was shifted
approximately 1 cm in the superior/inferior direction was also used. A typical beam
arrangement is shown in Figure 3. The daily fraction was delivered using all 4 fields daily. In
general, 45 Gy (relative biological effectiveness [RBE]) was delivered to the chest wall,
regional nodes, and supraclavicular fossa, followed by a cone down of an additional 5.4 Gy
(RBE) to the chest wall using an RBE value of 1.1. An additional boost to involved lymph
nodes, mastectomy scar, and tumor bed was used for select patients at physician discretion.
The median dose delivered to the comprehensive PTV was 50.4 Gy (RBE) [range, 45–65 Gy
(RBE)]. Setup accuracy was confirmed with daily X-ray verification of the isocenter based
on bony anatomy. For postlumpectomy patients, low-dose verification CTs were obtained 3
times during the course of treatment to ensure accurate setup and plan the tumor bed boost:
once on the day of simulation, another on week 1, and a third the week before the boost.
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Patients were seen weekly while on treatment, at 1 month after radiation therapy completion,
and at 3- to 6-month intervals thereafter. Skin toxicity, fatigue, esophagitis, lymphedema,
reconstructive complications, chest wall pain, and rib fracture were assessed using Common
Terminology Criteria for Adverse Events version 4.0. Toxicities were defined as occurring
any time after treatment initiation.

Results
Progression or recurrence
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Median follow-up was 9.3 months (range, 2.3–18.6 months) from the beginning of radiation
therapy. No patient experienced disease progression or recurrence during treatment. During
the follow-up period, 1 patient with cT3N3cM0, ypT1micN1M0 invasive ductal carcinoma
was treated with postmastectomy radiation therapy and developed isolated distant liver
metastases 10 months after completion of radiation therapy.
Dosimetry
There were 26 patients treated to the postmastectomy chest wall and regional nodes and 4
treated to the whole breast and regional lymphatics after lumpectomy. The internal
mammary nodes were treated at the physician’s discretion and included in the target in 28
patients (93.0%).
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Proton therapy generally achieved full coverage of the PTV (assessed by PTV V100 > 90%
and V95 > 95%). Protons also significantly spared organs at risk, including the heart, lungs,
and contralateral breast. The esophagus was constrained to a max point dose <100%, which
was achieved in the majority of patients. Dosimetry data are summarized in Table 2.
A representative dose distribution and dose–volume histogram of a treated patient are shown
in Figure 4.
Toxicity
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No patient required a treatment break. Among patients with >3 months of follow-up (n =
28), grade 2 dermatitis occurred in 20 patients (71.4%), and the incidence of moist
desquamation was 28.6% (n = 8). Figure 5 shows typical courses of the skin reactions for
patients undergoing treatment. Grade 2 skin pain occurred in 7 patients (25%). There were 8
patients (28.6%) who developed grade 2 esophagitis. All cases of esophagitis resolved
within the first month of follow-up. There were no cases of lung toxicity or cardiac toxicity.
One patient experienced a grade 3 reconstructive complication requiring removal of implant
and bilateral reconstruction in the setting of recurrent cellulitis and implant asymmetry.
There were no cases of chest wall pain or rib fracture.
Toxicities are summarized in Table 3.
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Discussion
Radiation therapy for breast cancer decreases postoperative local and regional recurrence,
thereby increasing overall survival. The targets to be covered for locally advanced breast
cancer are controversial, especially the IMN chain. All of the randomized trials that
established the role of postmastectomy radiation therapy (1–3) and the role of
comprehensive nodal treatment after lumpectomy (5, 6) included the IMN chain in the target
volume. However, targeting the IMNs with conventional techniques of photons or photonelectrons often leads to significant exposure to the lung and heart, and the potential benefit
in terms of disease control is offset by the increased risk of morbidity and mortality.
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The first source of this risk is cardiopulmonary toxicity. There is a well-established
incidence of cardiovascular events and coronary artery stenosis attributable to radiation
therapy, especially among patients with left-sided tumors (9–12). All levels of dose,
including intermediate and low doses, seem to drive the risk of cardiovascular disease.
Darby et al (7) recently demonstrated a linear correlation between the mean dose to the heart
and subsequent rates of ischemic heart disease among a large cohort of patients treated with
conventional radiation therapy for breast cancer, without any apparent threshold. There is a
similar risk pattern for radiation-induced pneumonitis. Although the data in breast cancer
patients are limited (22), several authors have found low-dose lung parameters, including the
volume receiving 10 Gy (V10) and 5 Gy (V5), to be significant predictors in patients treated
for breast and lung cancer (23–25).
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These data highlight the importance of heart- and lung-sparing approaches for breast
radiation therapy. With conventional techniques, limiting dose to these organs is mainly
achieved with the use of CT-guided planning, blocking, breath-hold techniques, and beam
angling. However, this often comes with a price of compromised target coverage, as shown
by Fontanilla et al (15). In that study the authors demonstrated that conventional photon
techniques with traditional field borders only cover approximately 75% of the chest wall,
84% of level 1, 88% of level 2, 96% of level 3, 84% of the supraclavicular lymph nodes, and
80% of the IMNs, as delineated by RTOG consensus guidelines.
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To counter this inadequate target coverage while still sparing the normal structures, some
practitioners have incorporated IMRT techniques for breast cancer. However, the increase in
homogeneity and target coverage from multifield IMRT results in a “low-dose bath” to
surrounding organs and creates a higher integral dose, mean lung dose, and mean heart dose.
Jagsi et al (26) recently compared 4 IMRT techniques for use in breast cancer, all of which
showed significant dose to the underlying heart and lungs (26). These high integral doses
and low-dose parameters may be associated with increased cardiopulmonary sequelae and
secondary cancers.
Protons are able to achieve homogenous target coverage without the low-dose exposure to
surrounding organs (27–29). The lower integral doses achieved with proton therapy has
translated into a significantly lower rate of secondary cancers when compared with photon
radiation therapy as assessed in one matched pair analysis of patients with a variety of
histologies treated to a variety of sites (30). Whether the sparing of the normal tissues by

Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2016 August 03.

Cuaron et al.

Page 6

Author Manuscript

proton therapy for breast cancer leads to reduced cardiovascular disease and secondary
cancers remains to be seen and is a topic of ongoing studies.
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The number of patients requiring treatment to the IMNs is likely to increase owing to the
insights gained from the recently published MA.20 and European Organization for Research
and Treatment of Cancer 22922 trials (5, 6). The projected expansion of indications for
comprehensive nodal irradiation requires a thorough evaluation of the safety and efficacy of
proton therapy as a treatment option. Reported clinical outcomes of protons for breast cancer
remain limited, especially in the treatment of patients with locally advanced disease and an
intact breast. To date, the published experience in the literature for patients with locally
advanced disease consists of a single phase 1/2 trial that showed proton therapy to be well
tolerated in the postmastectomy setting, with excellent target coverage and near-complete
sparing of organs at risk (19). However, this series had only 12 patients and did not include
any postlumpectomy patients. The present report represents the largest series to date of
patients with breast cancer treated with protons. Proton therapy consistently achieved
excellent coverage of the target, which included the IMNs in 93% of patients. A limited
number of patients were treated with an intact breast and to the regional lymph nodes, again
with complete coverage of the target volumes. The sparing of the heart, lung, and breast
tissue was dramatic and comparable to previously published proton reports, as shown in
Table 4.
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In the present study, the rate of moist desquamation was 28.6%, and there were no cases of
grade 3 dermatitis. This compares favorably to rates seen with both IMRT photons (31) and
conventional electrons (32) used in the postmastectomy setting. For patients who have
undergone postmastectomy reconstruction and require full dose to the skin, protons may
offer an advantage over photons with bolus. With uniform scanning proton therapy there is
100% dose at the skin without having to use bolus on the chest wall, which can lead to interand intratreatment variability because most bolus is not conformal over the implant.
However, this warrants further study, because there are also long-term concerns associated
with high surface doses to patients with implants. For those patients who do not require full
dose delivered to the skin, pencil beam scanning can offer proximal range modulation and
selective skin sparing, analogous to a photon beam without bolus.
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Notably, a significant number of patients experienced moderate esophagitis. The rates of
esophagitis among patients treated with sequential chemoradiation therapy for breast cancer
are not well described, but the 33% in the current series is presumed to be higher than what
would be expected with conventional techniques. There are 3 possible factors that
contributed to this relative increase. First, our current contouring practice of the
supraclavicular fossa covers the internal jugular vein and common carotid artery, in
accordance with the RTOG atlas for IMRT for breast cancer. This portion of the fossa does
not normally receive full dose when using conventional photon field borders (15). The
typical medial field edge of anterior oblique beam used in the conventional treatment of the
supraclavicular fossa is placed at the pedicle of vertebral body. By doing so, the esophagus is
almost completely blocked out of the field. However, this also creates significant
underdosing of the medial aspect of the supraclavicular fossa, although the concerns for
failure in this site are low. Second, in proton plans a portion of the upper breast or chest wall
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is included in the supraclavicular field, and beams require a more medial orientation. As a
result, the distal edge of the beam ends near the esophagus. Given the uncertainty of the
RBE at the distal edge of the Bragg peak, there could be slightly higher dose than
anticipated. This is in contrast to the laterally angled oblique portal used to treat the
supraclavicular field using photons. Last, the PTV expansion in the initial experience
resulted in a nontrivial amount of the upper esophagus being included within the PTV, and
likely contributed to the increased level of low-grade esophagitis seen in the present study.
As previously noted, our technique was later modified, and PTV overlap with the esophagus
was minimized. Importantly, all cases of esophagitis were easily managed in the outpatient
setting and had resolved by the first follow-up appointment.
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Although patient characteristics and treatment parameters were prospectively collected, this
study is retrospective in nature and conclusions are therefore limited. The number of patients
treated in the postlumpectomy setting was limited, and only those patients with small breasts
were selected owing to concerns with setup in larger-breasted women. In-room imaging
(such as AlignRT) would be helpful for a more robust setup for these patients. In addition,
follow-up is short, and further study is needed to assess for both locoregional control rates
and long-term toxicity. Additional follow-up is planned to further investigate the findings of
this report.

Conclusion
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In a series including 30 breast cancer patients treated with postoperative proton therapy to
the breast/chest wall and regional nodes, protons achieved excellent coverage of the target
volume, including the IMNs. The heart, lungs, and contralateral breast were well spared.
Integral doses to these organs were significantly lower than what would be expected from
conventional techniques. Treatment was well tolerated, with no grade 3 toxicities. The rate
of moist desquamation was acceptable and comparable to rates observed after photon
irradiation. Additional follow-up is planned to assess for long-term outcomes and toxicity.
Further study is needed to accurately select which patients stand to benefit from proton
therapy for breast cancer.
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Summary
This report represents the largest series of patients treated with proton therapy for breast
cancer. Dosimetry analysis showed excellent target coverage, which included the IMNs in
the majority of patients. The heart and lungs were effectively spared. Treatment was well
tolerated, and early toxicity was acceptable. Further study is planned to assess for longterm outcomes and toxicity.
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Fig. 1.

Lymph node groups were contoured per Radiation Therapy Oncology Group guidelines (A),
with the exception of the posterior portion of the supraclavicular fossa (red arrowheads),
which were included in the clinical target volume (B; red color wash) and planning target
volume (B; yellow color wash).
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Fig. 2.
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(A) The initial Proton Collaborative Group protocol included the clinical target volume
contoured to the edge of the esophagus, with expansion causing planning target volume (red
color wash) overlap with the esophagus (yellow color wash). (B) The protocol was later
modified to minimize planning target volume expansion and overlap around the esophagus.
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Fig. 3.

(A) A typical beam arrangement used to treat the unreconstructed chest wall and regional
lymph nodes. (B) Feathered junction with the match line shift superiorly by 1 cm for the
same patient as in (A).
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Fig. 4.

Representative dose distribution demonstrating full coverage of (A) internal mammary
lymph nodes and (B) heart sparing of a patient treated with postmastectomy proton radiation
to the left reconstructed chest wall, axilla, supraclavicular fossa, and internal mammary
lymph nodes. (C) Dose–volume histogram.
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Fig. 5.

Skin reactions of patients undergoing proton therapy to the chest wall and regional nodes
after mastectomy without reconstruction (top row) and after lumpectomy (bottom row). (A,
D) Baseline. (B, E) End of radiation therapy (RT). (C, F) One month follow-up after
radiation therapy.
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Patient characteristics
Age (y), median (range)

49 (29–86)

Stage
II

8 (26.7)

III

20 (66.7)

Chest wall recurrence

2 (6.7)

Histology
IDC

27 (90)

ILC

3 (10)

Side
Left

27 (90)

Right

3 (10)

Author Manuscript

Chemotherapy
Neoadjuvant

13 (43.3)

Adjuvant

14 (46.7)

Anthracycline-based

21 (70)

Concurrent herceptin

4 (13.3)

None

3 (10)

Surgery
Lumpectomy (BCS)
Chest wall wide local excision (recurrence)
Mastectomy + implant reconstruction

4 (13.3)
2 (6.7)
14 (46.7)

Mastectomy + autologous reconstruction

1 (3.3)

Mastectomy no reconstruction

9 (30)

Author Manuscript

Abbreviations: BCS = breast-conserving surgery; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma.
Values are number (percentage) unless otherwise noted.
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Table 2
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Dosimetry values
PTV
V100 (%)

89.20 (68.56–96.30)

V95 (%)

96.43 (79.39–99.60)

V110 (%)

13.30 (3.02–34.98)

Max point dose, Gy (RBE)

58.84 (50.8–70.5)

Heart (left-sided tumors, n=27)
Mean dose, Gy (RBE)

1.0 (0.09–3.20)

V20 (%)

1.16 (0–6.0)

V5 (%)

5.00 (0.17–14.40)

Max point dose, Gy (RBE)

22.80 (2.48–43.70)

Lungs

Author Manuscript

Total V20 (%)

7.31 (0.14–13.2)

Ipsilateral V20 (%)

16.50 (6.1–30.3)

Ipsilateral V5 (%)

34.35 (22.5–53.8)

Contralateral V5 (%)

0.34 (0–5.30)

Contralateral breast
Mean dose, Gy (RBE)
V5 (%)

0.29 (0.03–3.50)
1.46 (0–9.90)

Spinal cord
Max point dose, Gy (RBE)

1.24 (0–28.1)

Esophagus
Mean dose, Gy (RBE)

7.50 (0–19.59)

V30 (%)

10.80 (0–37.0)

Author Manuscript

V40 (%)

3.40 (0–28.9)

Max point dose, Gy (RBE)

45.65 (0–65.4)

Abbreviation: RBE = relative biological effectiveness.
Values are median (range).
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Table 3
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Acute toxicities
Toxicity
Dermatitis
Moist desquamation

Grade 1

Grade 2

Grade 3

7 (25)

20 (71.4)

0

N/A

8 (28.6)

0

Skin pain

3 (10.7)

7 (25)

0

Fatigue

13 (46.4)

1 (3.6)

0

Esophagitis

11 (39.3)

8 (28.6)

0

Lymphedema

8 (28.6)

0

0

Reconstructive complications

1 (3.6)

0

1 (3.6)

Chest wall pain

1 (3.6)

1 (3.6)

0

0

0

0

Rib fracture
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Values are number (percentage).
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NR
NR
38.03
NR
20.39

Heart V20 (%)

Heart V5 (%)

Ipsilateral lung
V20 (%)

Ipsilateral lung
V5 (%)

Total lung V20 (%)

14.4

NR

NR

NR

NR

7.5 Gy

NR

NR

65.00†
NR

25.30

NR

28.00

NR

65.00†

3.50 Gy

IMRT after
immediate
reconstruction*
(33)

46.00

NR

5-Field
mixed
photon/
electron (32)

Extrapolated from figure in publication.

†

Forward planned simplified IMRT using opposed lateral beams.

*

Abbreviations: IMRT = intensity modulated radiation therapy; NR = not reported.

NR

Heart (mean dose)

Parameter

Electrons
(30)

Photon/
electron
patch (31)

NR

65.00

28.00

56.00

13.00

8.69 Gy

IMRT
photons
(34)

NR

93.45

34.46

80.18

0.31

7.18 Gy

9-Field
IMRT
(25)

NR

54.00

29.49

10.15

0.40

2.60 Gy

Tangential
beamlet
IMRT (25)

12.70

25.20

16.20

4.10

1.60

0.44 Gy
(RBE)

Protons
(previous
series)
(19, 26)

Organ at risk median dosimetry for various techniques targeting internal mammary lymph nodes

7.31

34.35

16.50

5.00

1.16

1.00 Gy
(RBE)

Protons
(present
series)
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